12 Health Care Stocks Moving In Monday's After-Market Session
Allarity Therapeutics, Inc. ALLR | 1.16 | +2.65% |
Alps Group Inc ALPS | 1.01 | 0.00% |
Aprea Therapeutics APRE | 0.72 | +1.65% |
bioAffinity Technologies, Inc. BIAF | 3.92 | -1.51% |
China Pharma Holdings, Inc. CPHI | 0.63 | -1.56% |
Gainers
- China Pharma Holding (AMEX:CPHI) stock increased by 28.4% to $1.13 during Monday's after-market session. The company's market cap stands at $5.6 million.
- OSR Holdings (NASDAQ:OSRH) shares moved upwards by 6.92% to $0.6. The market value of their outstanding shares is at $14.9 million.
- Aprea Therapeutics (NASDAQ:APRE) stock increased by 4.95% to $0.79. The market value of their outstanding shares is at $5.5 million.
- Allarity Therapeutics (NASDAQ:ALLR) shares rose 4.75% to $1.01. The company's market cap stands at $16.0 million.
- ProMIS Neurosciences (NASDAQ:PMN) shares increased by 4.27% to $14.65. The market value of their outstanding shares is at $30.4 million.
- ALPS Group (NASDAQ:ALPS) shares increased by 3.59% to $1.02. The market value of their outstanding shares is at $161.3 million.
Losers
- bioAffinity Technologies (NASDAQ:BIAF) shares decreased by 11.8% to $1.12 during Monday's after-market session. The company's market cap stands at $5.1 million.
- Cypherpunk Technologies (NASDAQ:CYPH) stock decreased by 8.01% to $0.7. The company's market cap stands at $42.2 million.
- 60 Degrees (NASDAQ:SXTP) shares decreased by 5.77% to $3.43. The market value of their outstanding shares is at $5.3 million.
- Vivos Therapeutics (NASDAQ:VVOS) stock declined by 5.56% to $1.53. The market value of their outstanding shares is at $18.5 million.
- Zenas BioPharma (NASDAQ:ZBIO) stock declined by 3.59% to $17.5. The market value of their outstanding shares is at $986.0 million.
- SenesTech (NASDAQ:SNES) shares fell 3.45% to $1.96. The market value of their outstanding shares is at $9.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
